Abbott Laboratories
ABT
$116.64
+2.19%
Abbott Laboratories is a diversified healthcare company that develops and markets medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, operating across more than 160 countries. It holds a leading position in several high-growth niches, including continuous glucose monitoring (CGM) with its FreeStyle Libre system, cardiovascular devices, and point-of-care diagnostics, distinguishing itself as a broad-based healthcare innovator. The current investor narrative centers on the company's recovery from a challenging 2025-2026 period marked by a guidance cut in April 2026, which overshadowed a Q1 earnings beat and triggered a sharp selloff. However, recent momentum has been strong, with the stock rebounding over 24% in the past month, driven by renewed confidence in its medical device pipeline, strategic acquisitions, and defensive appeal amid broader market volatility.…
ABT
Abbott Laboratories
$116.64
Related headlines
Investment Opinion: Should I buy ABT Today?
Based on the analysis, ABT is rated a Buy. The consensus recommendation is Buy (mean rating 1.67), and the average price target of $119.40 implies 7.3% upside. The thesis is that Abbott's diversified healthcare portfolio, accelerating revenue growth, and improving margins will drive earnings growth that justifies the forward PE of 18.3x, which is below the industry average of 22x.
Sign up to view all
ABT 12-Month Price Forecast
The AI assessment leans bullish, driven by the company's accelerating revenue growth, improving margins, and attractive forward valuation. The recent rebound of 24.6% over the past month suggests improving investor sentiment, and the analyst consensus supports upside. However, the medium confidence reflects the uncertainty from the April guidance cut and the high trailing PE. If the company delivers on its growth promises and maintains margin expansion, the stock could re-rate higher; conversely, any negative surprises could quickly erode confidence. Key developments to watch include quarterly earnings, guidance updates, and competitive dynamics in the CGM market.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $119.40 and implied upside of +2.4% versus the current price.
Average Target
$119.40
0 analysts
Implied Upside
+2.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $135
Analyst target range
Abbott is covered by 25 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.67 (where 1 is Strong Buy and 5 is Sell). The average price target is $119.40, implying an upside of 7.3% from the current price of $111.25. The target range is $103.00 to $135.00, with the low target suggesting a potential downside of 7.4% and the high target implying an upside of 21.3%. The wide spread of $32 indicates significant uncertainty about the company's future performance. Recent institutional ratings have been overwhelmingly positive, with firms like Evercore ISI, Piper Sandler, and BTIG reiterating Buy or Overweight ratings in the past few months. This bullish sentiment is supported by the company's strong product pipeline and recent strategic moves, but the guidance cut in April 2026 remains a concern, as reflected in the low-end target.
Bulls vs Bears: ABT Investment Factors
Abbott presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth, margin expansion, a strong balance sheet, and a defensive business model, while the bear case hinges on the recent guidance cut, high trailing valuation, and underperformance relative to the market. Currently, the evidence slightly favors the bulls, given the strong Q1 beat, positive analyst sentiment, and the stock's recovery from its 52-week low. The most critical tension is whether the company can deliver the earnings growth implied by its forward PE of 18.3x, especially after the April guidance cut. If growth materializes, the stock is undervalued; if not, it could face further downside.
Bullish
- Strong Q1 revenue growth acceleration: Q1 2026 revenue grew 7.8% YoY to $11.164B, up from 4.9% growth in Q1 2025, indicating accelerating demand across medical devices and diagnostics. This momentum supports the company's recovery narrative and forward growth expectations.
- Improving gross margin: Gross margin expanded to 56.3% in Q1 2026 from 52.6% in Q1 2025, reflecting favorable product mix and cost controls. This margin expansion is a key driver of the expected EPS growth, as the forward PE of 18.3x implies significant profitability improvement.
- Strong analyst consensus and upside: With 25 analysts, the consensus is Buy (mean rating 1.67) and the average price target is $119.40, implying 7.3% upside from the current price of $111.25. The high target of $135 suggests 21.3% upside, reflecting confidence in the pipeline and recovery.
- Defensive appeal with low beta: ABT's beta of 0.581 indicates lower volatility than the market, making it an attractive defensive holding during economic uncertainty. This is reinforced by its 1.88% dividend yield and 409th consecutive quarterly dividend, providing income stability.
Bearish
- Guidance cut in April 2026: Abbott lowered its 2026 profit outlook in April, overshadowing a Q1 earnings beat and triggering a sharp selloff. This guidance cut signals potential near-term headwinds, including pricing pressures or slower-than-expected recovery in certain segments, and remains a key overhang.
- High trailing PE relative to peers: The trailing PE of 33.5x is 52% above the industry average of 22x, indicating the stock is not cheap on current earnings. If growth expectations are not met, the stock could face valuation compression.
- Negative 1-year price performance: ABT is down 13.9% over the past year, underperforming the S&P 500, which gained 20.4% over the same period. This relative weakness suggests persistent investor skepticism despite the recent rebound.
- Free cash flow volatility: Q1 2026 free cash flow was $916M, down significantly from $2.626B in Q4 2025, indicating potential lumpiness in cash generation. This could impact the company's ability to sustain dividend growth or fund acquisitions if the trend continues.
ABT Technical Analysis
Abbott's stock has experienced a volatile year, with a 1-year price change of -13.9%, but it is currently in a strong recovery phase. The stock is trading at $111.25, which is 81% of its 52-week range (low: $81.97, high: $137.49), indicating a significant rebound from the lows but still below the highs. This positioning suggests that while the stock has recovered substantially, it has not yet regained its previous peak, leaving room for further upside if momentum continues. The 52-week low was set in May 2026, and the subsequent rally has been robust, but the stock remains 19% below its 52-week high, reflecting lingering caution among investors.
Beta
0.58
0.58x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$82-$137
Price range past year
Annual Return
-11.6%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +16.0% | +2.5% |
| 3m | +33.4% | +2.7% |
| 6m | +3.9% | +11.1% |
| 1y | -11.6% | +20.5% |
| ytd | -6.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
In Q1 2026, Abbott reported revenue of $11.164 billion, a 7.8% year-over-year increase, accelerating from the 4.9% growth seen in Q1 2025. This growth was driven by strong performance in Medical Devices (revenue $5.539 billion) and Diagnostic Products ($6.2 billion), which together account for the majority of sales. The company's net income for Q1 was $1.077 billion, with EPS of $0.62, down from $1.02 in Q4 2025 but up from $0.76 in Q1 2025. Gross margin improved to 56.3% in Q1 2026, up from 52.6% in the year-ago quarter, reflecting favorable product mix and cost controls. Operating margin was 16.5%, slightly below the 19.6% in Q4 2025 but above the 16.3% in Q1 2025, indicating stable profitability. The company's balance sheet remains solid, with a debt-to-equity ratio of 0.29 and a current ratio of 1.58, indicating ample liquidity. Free cash flow for Q1 was $916 million, down from $2.626 billion in Q4 2025 but positive, and the company generated $1.315 billion in operating cash flow. ROE stands at 12.5%, and the company pays a dividend with a yield of 1.88%, supported by a payout ratio of 63%.
Quarterly Revenue
$11.2B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
56.3%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE is 33.5x, while the forward PE is 18.3x, indicating that the market expects significant earnings growth in the next year. This gap suggests that the market is pricing in a strong recovery in profitability, likely driven by margin expansion and continued revenue growth. Compared to the industry average PE of 22x (based on available data), Abbott trades at a 52% premium on a trailing basis, but on a forward basis, it is at a 17% discount, reflecting the market's expectation of above-average growth. Historically, Abbott's PE has ranged from 21x to 46x over the past five years, with the current trailing PE of 33.5x near the middle of that range. The forward PE of 18.3x is near the lower end, suggesting that the stock is attractively valued relative to its own history if the growth expectations are met.
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high trailing PE of 33.5x, which leaves little room for error; if earnings disappoint, the stock could de-rate significantly. The company's free cash flow dropped to $916M in Q1 2026 from $2.626B in Q4 2025, indicating potential volatility in cash generation, which could pressure dividend growth or acquisition capacity. However, the debt-to-equity ratio of 0.29 is conservative, and the current ratio of 1.58 provides ample liquidity, mitigating near-term solvency concerns. The payout ratio of 63% is manageable, but a sustained FCF decline could force a dividend cut, which would be a major negative catalyst.